Tysabri® (natalizumab) Injection

Tysabri (natalizumab) is covered for adults (≥18) only for FDA‑approved relapsing forms of multiple sclerosis and for moderately‑to‑severely active Crohn’s disease with objective inflammation after prior therapy failures (non‑FDA uses and patients <18 are excluded). Coverage requires specialist prescribing/consultation (neurologist for MS, gastroenterologist for CD), specified prior‑therapy failures (MS: ≥1 DMT failure or documented highly‑active disease; CD: ≥2 biologic failures), documentation of objective benefit for reauthorization, dosing 300 mg IV every 4 weeks, and authorization limits (MS: 12 months; CD initial: 6 months, reauthorization: 12 months).

"Multiple Sclerosis (MS): Tysabri is indicated as monotherapy for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and ac..."

Sign up to see full coverage criteria, indications, and limitations.